Sagient ResearchProductsAbout UsContact Us

    SAMPLE COMPANY PROFILE
(Data Shown as of 05/13/10)
  Amylin Pharmaceuticals, Inc. (AMLN)     
  http://www.amylin.com/

  Pipeline Summary :   Company Report: N/A
    Company Valuation: View
 
Pipeline Valuation
Market Price: $17.69
Market Cap: $2.51B
Burn Rate (-)/ Cash Flow (+): $-6.99M
Cash/Marketable Securities: $598.25M
Quarters of Cash Left: 85.56
Estimated Pipeline Value per Share: 2015 2020
At Enterprise Value/EBITDA of  25: 22.02* 13.00*
Probability Adjusted Revenue (M): 873.0 1080.8
Estimated EBITDA (M): 322.1 390.1
Assumptions  Explanation *See Research Standards

Show All Catalysts
Expected Event Expected Event Date
Company - Analyst/R&D Update   06/27/2010
Company - Earnings Announcement   07/19/2010 - 07/28/2010
Company - Earnings Announcement   10/18/2010 - 10/28/2010
 
(View 10 Year Revenue Outlook: U.S.   Worldwide)


Name Lead/Partner Indication Phase Est. Approval Date Likelihood of Approval Clinical Trial
Analysis
(Last Event)		 Peak U.S. Revenue (M) Upcoming Catalyst
AC162352 Lead Obesity Suspended N/A N/A View Analysis
(11/28/07)		 N/A
AC2592 Lead Congestive Heart Failure (CHF) Suspended N/A N/A View Analysis
(06/29/07)		 N/A
Bydureon Lead Diabetes Mellitus, Type II NDA 10/10 95%
(14% Above Avg.)		 View Analysis
(05/06/10)		 $ 1,431.5 Now - 05/31/10
Byetta Lead Diabetes Mellitus, Type II Approved 04/05 100%
(Same As Avg.)		 View Analysis
(02/26/10)		 $ 567.1
Obesity Suspended N/A N/A View Analysis
(03/27/09)		 N/A
Davalintide Partner Obesity Suspended N/A N/A View Analysis
(02/22/10)		 N/A
Exenatide transdermal patch Lead Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.)		 View Analysis
(04/19/10)		 N/A
Intranasal exenatide Lead Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.)		 View Analysis
(01/27/10)		 N/A
Metreleptin Lead Lipodystrophy IND N/A N/A View Analysis
(04/19/10)		 N/A 10/01/10 - 12/31/10
Symlin (Pramlintide) Lead Diabetes Mellitus, Type II Approved 03/05 100%
(Same As Avg.)		 View Analysis
(06/09/09)		 $ 74.5
Diabetes Mellitus, Type I Approved 03/05 100%
(Same As Avg.)		 View Analysis
(10/17/07)		 $ 20.7 Now - 12/31/10
Obesity Suspended N/A N/A View Analysis
(10/29/08)		 N/A
Symlin and Metreleptin Partner Obesity IIb 01/15 35%
(5% Above Avg.)		 View Analysis
(04/19/10)		 $ 471.4 01/01/11 - 12/31/11

Amylin Pharmaceuticals was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates, focusing research and clinical expertise in metabolic medicine including the areas of diabetes, obesity and cardiovascular disease.

 
 Questions? Email Subscriber Support BioMedTracker Research Standards      Privacy Policy      Important Legal Disclosure 

Copyright © 2010 Sagient Research Systems, Inc.  All rights reserved.